Exelixis Expands Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb To Include Fixed-Dose Combination Of Nivolumab And Relatlimab In Combination With XL092 In Phase 1b STELLAR-002 Trial
Agreement enables evaluation of XL092 in combination with an additional immune checkpoint inhibitor —
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ:EXEL) today announced the expansion of its June 2021
Exelixis Announces Detailed Results From Late-Stage Cabometyx Combo Trial In Kidney Cancer
Exelixis Inc (NASDAQ:EXEL) announced detailed results from the COSMIC-313 Phase 3 trial cabozantinib (Cabometyx), nivolumab, and ipilimumab combo in untreated advanced…
Exelixis Q2 EPS $0.28 Beats $0.19 Estimate, Sales $419.43M Beat $390.91M Estimate
Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.19 by 47.37 percent. This is a 24.32 percent decrease over earnings of $0.37 per share from the same
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $23
Morgan Stanley analyst Jeffrey Hung maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $22 to $23.
The Daily Biotech Pulse: Merck’s Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours:
